Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Holders of 5% or more of VRDN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Viridian Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 13D/A | 15.14%16.0M shares | – | Oct 27, 20251 filing | Oct 27, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
8 Schedule 13D and 13G filings on Viridian Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 20261:55 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 202612:52 PM ET | Kynam Capital Management, LPand 2 others | 13G/A | 1.54%1.47M shares | −4.22 ppfrom 5.76%Below 5% | Dec 31, 2025 | SEC |
| Feb 13, 20268:53 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 2.65%2.52M shares | –Below 5% | Dec 31, 2025 | SEC |
| Nov 14, 20255:17 PM ET | Commodore Capital LPand 1 other | 13G/A | 3.90%3.20M shares | −1.40 ppfrom 5.30%Below 5% | Sep 30, 2025 | SEC |
| Oct 27, 20254:31 PM ET | Fairmount Funds Management LLCand 1 other | 13D/A | 15.14%16.0M shares | – | Oct 23, 2025 | SEC |
| May 15, 202511:44 AM ET | Kynam Capital Management, LPand 2 others | 13G | 5.76%0 shares | New | Mar 31, 2025 | SEC |
| Apr 11, 20255:15 PM ET | Commodore Capital LPand 1 other | 13G | 5.30%4.30M shares | New | Apr 4, 2025 | SEC |
| Feb 14, 20256:05 PM ET | Venrock Healthcare Capital Partners III, L.P.and 6 others | 13G/A | 4.50%3.58M shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Viridian Therapeutics, Inc. shares.
No Form 144 notices for Viridian Therapeutics, Inc. are on file.